Opioid use disorder (OUD) is a growing crisis in the United States, with more than 130 people dying each day and drug overdose becoming the number one cause of death for people under 50 years old. Buprenorphine, a partial agonist at the mu-receptor has been demonstrated to be effective as a daily sublingual/transmucosal dosing for over a decade. However, there are many challenges with daily oral dosing, including potential for misuse, abuse, and the need to make a choice every day to adhere to treatment. Addnl., in those with small childeren, pediatric exposure to oral forms of buprenorphine has lead to increasing emergency room visits. Lastly, oral forms of buprenorphine as become one of the most diverted products in the recent years, increasing illicit use of buprenorphine. Several long-acting buprenorphine products have been in development including a 6-mo implant and weekly and monthly depot injections. CAM2038 (BRIXADI) is a lipid-based formulation based on the characteristics of low-viscosity lipids, which in contact with aqueous media transforms into a reversed-phase "water-in-oil" monlamellar liquid crystal nanopartical gel (FluidCrystal). This delivery system allows for buprenorphine to be delivered thorugh a small 23-gauge needle in a pre-filled syringe in both weekly and monthly dose regimens with multiple flexible doses. BRIXADI was studied in seven Phase 1-3 clin. studies, including a Phase 2 opioid blockade study, demonstrating complete blockade Drug Liking with a full mu-receptor agonist, and two Phase 3 studies which established both safety and efficacy in the treatment of patients with OUD. This presentation will provide background on the delivery system for BRIXADI weekly and monthly and overview of the clin. program, including results from the efficacy and safety studies.